News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|December 23, 2024

Advancing IgA Nephropathy Care: Emerging Therapies, Unmet Needs, and Economic Considerations

Episodes in this series

EP. 1 Advancing IgA Nephropathy Care: Emerging Therapies, Unmet Needs, and Economic Considerations

EP. 1 Advancing IgA Nephropathy Care: Emerging Therapies, Unmet Needs, and Economic Considerations

4 experts are featured in this series.

EP. 2 Introduction to IgA Nephropathy

4 experts are featured in this series.

EP. 3 Pathogenesis of IgA Nephropathy: The 4-Hit Cascade, A Proliferation-Inducing Ligand (APRIL), and cytokines

4 experts are featured in this series.

EP. 4 Diagnosing IgA Nephropathy

4 experts are featured in this series.

EP. 5 Signs and Symptoms of IgA Nephropathy

4 experts are featured in this series.

EP. 6 Challenges in Timely Identification of IgA Nephropathy

4 experts are featured in this series.

EP. 7 Clinical Impact of IgA Nephropathy and Quality of Life

4 experts are featured in this series.

EP. 8 Overview of Treatment Landscape for IgA Nephropathy: Standard of Care and KDIGO Guidelines

4 experts are featured in this series.

EP. 9 Current Treatments for IgA Nephropathy and the 4-Hit Cascade

4 experts are featured in this series.

EP. 10 Gaps in Patient Care for IgA Nephropathy

4 experts are featured in this series.

EP. 11 Emerging Anti-BAFF and Anti-APRIL Therapies

4 experts are featured in this series.

EP. 12 Emerging Therapies: Other Strategies and Important Considerations

4 experts are featured in this series.

EP. 13 The Promise of Emerging Therapies for IgA Nephropathy and Future KDIGO Guidelines

4 experts are featured in this series.

EP. 14 Sequencing and Individualizing Treatments for IgA Nephropathy

4 experts are featured in this series.

EP. 15 Measuring Success in IgA Nephropathy in Clinical Practice

4 experts are featured in this series.

EP. 16 Economic Impact of IgA Nephropathy for Patients

4 experts are featured in this series.

EP. 17 Early Diagnosis and Cost Mitigation in IgA Nephropathy

4 experts are featured in this series.

EP. 18 Cost Implications of Modulating IgA Nephropathy Disease Course

4 experts are featured in this series.

EP. 19 Patient-Reported Outcomes in the Treatment of IgA Nephropathy

4 experts are featured in this series.

EP. 20 Future Possibilities for Step Therapy in IgA Nephropathy Treatment

4 experts are featured in this series.

EP. 21 Key Managed Care Considerations for IgA Nephropathy Treatment

4 experts are featured in this series.

EP. 22 Key Economic Considerations in IgA Nephropathy: Progression to Chronic Kidney Disease

4 experts are featured in this series.

EP. 23 Closing Thoughts About IgA Nephropathy Treatment

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

2 experts are featured in this video

Why Hepatitis B and Hepatitis C Cures Are Fundamentally Different

ByRaymond Chung, MD,Douglas Dieterich, MD

August 27th 2026

2 experts are featured in this video

Unmet Needs and Long-Term Antiviral Safety in Hepatitis B Care

ByRaymond Chung, MD,Douglas Dieterich, MD

August 27th 2026

Inside the Pivotal Trials Shaping Vitiligo Treatment Choices

ByRyan Haumschild, PharmD, MBA,David Rosmarin, MD,Seemal R. Desai, MD, FAAD,Jason Fehr, MA,Karan Lal, DO, MS, FAAD

August 26th 2026

Payer Perspectives on Topical Versus Oral JAK Selectivity

ByRyan Haumschild, PharmD, MBA,David Rosmarin, MD,Seemal R. Desai, MD, FAAD,Jason Fehr, MA,Karan Lal, DO, MS, FAAD

August 26th 2026

5 experts are featured in this series

Catching Alzheimer's Disease Early: Assessing Mild Cognitive Impairment in Primary Care

ByKavita Nair, PhD,Joshua Oaks, MD,Scott Joy, MD, MBA, FACP,Jennifer Woodward, MD, MPH,Dylan Gallacher, PA

August 25th 2026

Trending on AJMC

Daraxonrasib Clears FDA as First RAS-Targeted Pancreatic Cancer Drug

As GLP-1 Costs Climb, Medicare Part D Plans Face a Reckoning

ACO-SWITCH to Evaluate Tafamidis-to-Acoramidis Switch in ATTR-CM

FAQ: Prior Authorization Reform—Will Changes Go Far Enough by 2027?

Framework Charts a 3-Stage Path to Catch Psoriatic Arthritis Early